Brookstone Capital Management raised its position in Encompass Health Co. (NYSE:EHC – Get Rating) by 19.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,245 shares of the company's stock after purchasing an additional 1,821 shares during the period. Brookstone Capital Management's holdings in Encompass Health were worth $544,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Baupost Group LLC MA increased its position in shares of Encompass Health by 318.9% in the 1st quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock valued at $213,330,000 after buying an additional 2,283,900 shares in the last quarter. State Street Corp lifted its holdings in shares of Encompass Health by 5.0% during the 1st quarter. State Street Corp now owns 2,733,254 shares of the company's stock valued at $195,118,000 after purchasing an additional 130,504 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Encompass Health by 33.3% in the 1st quarter. Bank of New York Mellon Corp now owns 2,099,763 shares of the company's stock valued at $149,314,000 after purchasing an additional 524,766 shares during the period. Dimensional Fund Advisors LP increased its stake in Encompass Health by 21.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,464,313 shares of the company's stock worth $104,127,000 after purchasing an additional 254,385 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Encompass Health by 14.0% during the 4th quarter. Invesco Ltd. now owns 1,389,517 shares of the company's stock worth $90,679,000 after buying an additional 170,155 shares during the period. 93.07% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Stock Performance

EHC opened at $47.72 on Friday. Encompass Health Co. has a 52-week low of $44.33 and a 52-week high of $77.74. The firm has a market capitalization of $4.76 billion, a PE ratio of 14.59, a PEG ratio of 2.32 and a beta of 1.02. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.24 and a current ratio of 1.24. The business's 50-day simple moving average is $50.75 and its 200 day simple moving average is $59.04.

Encompass Health Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Monday, October 3rd will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, September 30th. This represents a $0.60 annualized dividend and a yield of 1.26%. Encompass Health's payout ratio is presently 34.25%.

Analyst Ratings Changes

EHC has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Encompass Health from $80.00 to $62.00 in a report on Wednesday, August 3rd. Stephens reduced their target price on shares of Encompass Health from $78.00 to $74.00 and set an "overweight" rating for the company in a research note on Tuesday, June 21st. Truist Financial reduced their price objective on Encompass Health from $75.00 to $65.00 and set a "buy" rating for the company in a research report on Monday, August 8th. Royal Bank of Canada dropped their target price on Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. Finally, Credit Suisse Group reduced their price target on Encompass Health from $63.00 to $62.00 and set an "outperform" rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Encompass Health currently has an average rating of "Buy" and a consensus price target of $66.89.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 20,449 shares of the company's stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $53.25, for a total value of $1,088,909.25. Following the sale, the chief executive officer now owns 440,895 shares in the company, valued at $23,477,658.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is currently owned by corporate insiders.

Encompass Health Company Profile

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Read More

• Get a free copy of the StockNews.com research report on Encompass Health (EHC)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• 2 Semiconductor Stocks To Watch For Reversals

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Get Rating).

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.